A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of chronic hepatitis B: results at week 96

徐京杭,于岩岩,斯崇文,曾争,李军,毛青,张大志,唐红,盛吉芳
DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2014.10.005
2014-01-01
Abstract:Objective To evaluate the efficacy and safety of entecavir (ETV) versus ETV maleate in Chinese patients with chronic hepatitis B (CHB).Methods This was a randomized,double blind,double-dummy,controlled,multicenter study.Patients were randomly assigned to receive 48 weeks of treatment with 0.5 mg/d ETV or 0.5 mg/d ETV maleate,then all patients received the treatment with 0.5 mg/d ETV maleate since week 49.Patients were regularly followed up.Serum hepatitis B virus (HBV) markers were detected.Adverse events (AE) were recorded.Quantitative data accorded with normal distribution were analyzed by t test.Quantitative data with abnormal distribution were analyzed by Wilcoxon test.Chi square test or Fisher exact test were used for categorical data.Results Two hundred and eighteen patients with hepatitis B e antigen (HBeAg)-positive CHB (110 in ETV group and 108 in ETV maleate group) and 57 patients with HBeAg-negative CHB (26 in ETV group and 31 in ETV maleate group) were enrolled.Baseline characteristics were well balanced between the two groups.For the patients with HBeAg-positive CHB,the mean HBV DNA levels in ETV group and ETV maleate group were similarly decreased from baseline (by 5.90 lg IU/mL vs by 5.84 lg IU/mL; F=0.07,P=0.785) at week 96.Patients who achieved undetectable levels of serum HBV DNA (<20 IU/mL) at week 96 were similar in the two groups (58.18% vs 56.48%;x2=0.06,P=0.800).Both groups achieved similar HBeAg loss rates at week 96 (29.1% vs 24.1%; x2 =0.70,P=0.402).Both groups achieved similar HBeAg seroconversion rates at week 96 (12.6% vs 12.3% ;x2 =0.01,P=0.938).Both groups achieved similar alanine aminotransferase (ALT) normalization rate at week 96 (87.5% vs 85.7% ; x2 =0.14,P=0.709).For the patients with HBeAg-negative CHB,the mean HBV DNA levels in both groups were similarly decreased from baseline (by 5.72 lg IU/mL vs by 5.60 lg IU/mL; F=0.10,P=0.758) at week 96.Patients who achieved undetectable levels of serum HBV DNA at week 96 were similar in the two groups (96.2% vs 96.8%; P=1.000).Both groups achieved similar ALT normalization rate at week 96 (91.7% vs 90.3%; P=1.000).The overall incidence of AE was similar in both groups (21.32% vs 18.71%; x2=0.29,P=0.587).Conclusion Entecavir maleate and entecavir have similar efficacy and safety in patients with CHB.
What problem does this paper attempt to address?